“Our Growing Resistance to Antibiotics”, a resource produced by Georgetown University, discusses the challenge and risks of the antibiotic overuse, how to empower patients to ask questions about prescriptions, and the importance of preventing resistance to ensure that antibiotics remain effective. A valuable resource for anyone from the antimicrobial resistance (AMR) community.
One defining moment fundamentally changed the course of Dr Ravina Kullar’s personal and professional life. It was the pivotal moment that led her into specialising in infectious diseases and taking action in the fight against antibiotic resistance, which is projected to kill more than 10 million people worldwide per year by 2050.
CO-ADD's Mark Blaskovich discusses recent 'superbug' news headlines in The Conversation - in English and Indonesian!
An antibiotic overlooked since its discovery 40 years ago could help develop new drugs against life-threatening infections caused by some of the world’s most dangerous superbugs.
University of Queensland Institute for Molecular Bioscience (IMB) researchers synthesised the antibiotic, and increased its effectiveness against extensively drug-resistant bacteria, then collaborated with Monash University to evaluate the drug using animal models of infection.
An extra membrane camouflages Gram-negative bacteria from drugs and the immune system.
13 December: Collaborative Drug Discovery (CDD) will host a webinar discussing an innovative collaboration in the discovery and development of drugs to treat Tuberculosis
Missed the National AMR Forum? Read a recap of the Forum and CO-ADD's Drug Discovery & Development Workshop below.
Researchers from the Community for Open Antimicrobial Drug Discovery (CO-ADD) have been awarded almost $1 million to develop a new antibiotic that could treat life-threatening bacterial infections resistant to all known antibiotics.
Join CO-ADD on Thursday 2 November for a workshop on the ins and outs of drug discovery and development, part of the National AMR Forum to be held in Brisbane, Australia
A global conference taking place in Berlin in October will accelerate action on tackling drug-resistant infections, one of the greatest health and economic challenges of our time.
CO-ADD tests compounds against five of the top pathogens listed on the WHO priority list for R&D of new antibiotics: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus, as well as the fungi Cryptococcus neoformans and Candida albicans.
“We welcome the published list of priority pathogens to be worked on from the World Health Organization. Our research targets five of the pathogens listed, including the three most critical. This will be a vital tool that will guide antibiotic research and drug discovery for the future,” said CO-ADD Dr Mark Blaskovich.
CO-ADD media enquiries: r.neale1@uq.edu.au; +61 (0) 733462389
